Everyone Healthy Library
Hypertrophic Cardiomyopathy
Also Known As: Asymmetic Septal Hypertrophy (ASH)
Condition / disease reference page from the Everyone Healthy database.
! Seek urgent medical care if warning signs appear
Some health conditions or symptoms can become urgent. Use this page for education, but seek help quickly if warning signs are present.
Get urgent medical care now if there is any severe, sudden, rapidly worsening or worrying symptom, especially:
- chest pain, pressure or pain spreading to the arm, jaw or back
- trouble breathing, blue lips, severe wheeze or choking
- stroke-like symptoms such as face drooping, arm weakness or speech trouble
- collapse, fainting, seizure, confusion or extreme drowsiness
- severe bleeding, black stools, vomiting blood or major injury
- severe allergic reaction, swelling of the face/throat or widespread rash with breathing trouble
- severe abdominal pain, severe headache, stiff neck or sudden vision change
- signs of severe dehydration, sepsis, high fever with worsening illness, or symptoms in a baby/young child that concern you
Connected health information
Explore this condition in a clear order
Condition overview
Attributes
Incidenceis approximately 1 in 5,000 people
Linked signs and symptoms
11Each sign/symptom opens its own page and links back to related conditions.
Linked drugs / medications
1Medication information is educational only. A doctor or pharmacist should advise whether any medicine is appropriate.
Treatments, therapies and supportive options
10Grouped by treatment type. These are educational database links, not personal treatment recommendations. Evidence labels are shown only where stored in the EH database.
Surgery
4Medical therapy
5Linked diagnostic tests and investigations
6These are pulled from both EH diagnostic-test link tables, including the older large test-link table.
Biological markers/agents
6This visual map shows biological markers/agents reported as increased or decreased with this condition. These are educational relationships only; test results must be interpreted by a qualified clinician because ranges vary by lab, method, age, sex and clinical context.
Often increased
6- 2,3 Diphosphoglycerate (2,3-DPG)Reference range exampleAdult ( > 16y): 10.5–14 µmol/gLinked diagnostic tests2, 3 Diphosphoglycerate (2
- FibrinogenReference range exampleAdult ( > 16y): 150–400 mg/dLLinked diagnostic testsFibrinogen Concentration test
- Hemoglobin (Hb)Reference range exampleFemale: 78–100 gm/dL; Male: 76–100 gm/dLLinked diagnostic testsHemoglobin (Hb) Concentration, Mean Corpuscular Hemoglobin (MCH) Weight Test
- HomocysteineReference range exampleAll, Female: 4–15 µmol/L; All, Male: 7–16 µmol/LLinked diagnostic testsHomocysteine Concentration (HCY, Blood)
- RBC MassReference range exampleFemale: 36–48 %; Male: 42–52 %Linked diagnostic testsHeamatocrit (Hct)
- Red Blood Cells (RBC)Reference range exampleAdult ( > 16y), Female: 3.6–5 106/mm3; Adult ( > 16y), Male: 4.2–5.4 106/mm3Linked diagnostic testsRed Blood Cell (RBC) Count
Often decreased
0No markers in this group.
Introduction / full article
Hypertrophic Cardiomyopathy
Summary References
Treatments:
1. http://www.merck.com/mmpe/sec07/ch084666/ch084666c.html?qt=hypertrophic%20cardiomyopathy&alt=sh#S08_CH84666_CH84666c-27
2. Maron BJ (Mar 2002). "Hypertrophic cardiomyopathy: a systematic review". JAMA 287 (10): 1308–20. doi:
Sherrid MV, Chaudhry FA, Swistel DG (Feb 2003). "Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction". Ann Thorac Surg. 75 (2): 620–32. doi:
Wigle ED, Rakowski H, Kimball BP, Williams WG (Oct 1995). "Hypertrophic cardiomyopathy. Clinical spectrum and treatment". Circulation 92 (7): 1680–92.
5. Maron BJ, McKenna WJ, Danielson GK, et al. (Nov 2003). "American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines". J Am Coll Cardiol 42 (9): 1687–713.
6. Sherrid MV, Barac I, McKenna WJ, et al. (Apr 2005). "Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy". J Am Coll Cardiol. 45 (8): 1251–8. doi:
Morrow AG (Oct 1978). "Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction". J Thorac Cardiovasc Surg. 76 (4): 423–30
8. Brilakis ES, Nishimura RA (Jul 2003). "Severe pulmonary hypertension in a patient with hypertrophic cardiomyopathy: response to alcohol septal ablation". Heart 89 (7): 790. doi:. PMID 12807862
9. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ (July 1999). "Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points". J Am Coll Cardiol 34 (1): 191–6. doi: